OnCo
journalsJournal

Cancer Discovery

aka Cancer Discov

AACR's high-profile journal bridging discovery and the clinic: first-in-human targeted-therapy data, resistance mechanisms and translational biology.

Cancer Discovery has appeared monthly since 2011 and publishes early clinical results with deep correlative science (KRAS, menin, and other targeted agents' first reports), mechanisms of acquired resistance, and the AACR Cancer Progress Report coverage. Hybrid access; AACR annual meeting plenary papers frequently appear here.

Publisher
American Association for Cancer Research · American Association for Cancer Research
Scope
basic cancer biology
Access model
hybrid
Founded
2011
ISSN
2159-8274
Impact factor (2023)
29.7 · Clarivate Journal Citation Reports 2024 (2023 JIF)

Key papers published here

1top

People

7top
Andrew J. Aguirre
Institute Member, Broad; Physician, Dana-Farber
Pancreatic cancerKRAS biologyOrganoids

Uses organoids and functional genomics to find what pancreatic cancers depend on beyond KRAS.

David A. Tuveson
Director, CSHL Cancer Center; Roy J. Zuckerberg Professor
Pancreatic cancerOrganoidsTumour stroma

Built the pancreatic cancer organoid models now used to test drugs against a patient's own tumour.

Jeeyun Lee
Professor of Medical Oncology; gastrointestinal cancer and precision oncology
Gastric cancerPrecision oncologyMolecular profiling

A gastric cancer trialist who pioneered biomarker-driven umbrella trials in Korea and helped bring HER2 and Claudin 18.2 agents to Asian patients.

Maximilian Diehn
Professor of Radiation Oncology, Stanford University
Radiation oncologyCirculating tumour DNALung cancer

Radiation oncologist who showed a blood test can detect leftover lung cancer months before scans.

Nina Bhardwaj
Director of Immunotherapy; Ward-Coleman Chair in Cancer Research
Dendritic cellsCancer vaccinesPersonalised neoantigen vaccines

Nina Bhardwaj is a dendritic-cell immunologist running personalised neoantigen vaccine trials.

Ryan B. Corcoran
Director, Gastrointestinal Cancer Center; Scientific Director, Termeer Center for Targeted Therapy
Colorectal cancerBRAF and KRAS resistanceLiquid biopsy

Worked out why BRAF inhibitors fail in colorectal cancer and how to combine drugs to overcome it.

Stefan Fröhling
Managing Director, NCT Heidelberg; Head of Translational Medical Oncology, DKFZ
Precision oncologySarcomaGenomics-guided trials

Runs the NCT/DKTK MASTER programme that sequences whole genomes of rare and young-adult cancers to guide therapy.

Connected

3top